These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38837909)

  • 21. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy.
    Jahanafrooz Z; Oroojalian F; Mokhtarzadeh A; Rahdar A; Díez-Pascual AM
    Drug Dev Res; 2024 Aug; 85(5):e22244. PubMed ID: 39138855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual Adjuvant-Loaded Peptide Antigen Self-Assembly Potentiates Dendritic Cell-Mediated Tumor Immunotherapy.
    Kim J; Kang S; Kim J; Yong SB; Lahiji SF; Kim YH
    Adv Sci (Weinh); 2024 Sep; 11(36):e2403663. PubMed ID: 39073756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine.
    Yang C; Chen Y; Liu J; Zhang W; He Y; Chen F; Xie X; Tang J; Guan S; Shao D; Wang Z; Wang L
    Adv Sci (Weinh); 2024 Aug; 11(30):e2400630. PubMed ID: 38867377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano-Vaccine for Overcoming Immune Barriers for Effective and Long-Term Cancer Immunotherapy.
    Wang C; Zhao J; Duan Y; Lin L; Zhang Q; Zheng H; Shan W; Wang X; Ren L
    Adv Healthc Mater; 2024 Oct; 13(26):e2401416. PubMed ID: 38848734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
    Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
    ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
    Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
    Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint reprogramming via sequential nucleic acid delivery strategy optimizes systemic immune responses for gastrointestinal cancer immunotherapy.
    Li Z; Liu X; Cai N; Zhou Z; Huang H; Wu Q; Xu L; Zhu WG; Zhang C; Wei Z; Li D
    Cancer Lett; 2024 Sep; 599():217152. PubMed ID: 39094825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Biomimetic Autophagosomes-Based Nanovaccine Boosts Anticancer Immunity.
    Qu L; Cui G; Sun Y; Ye R; Sun Y; Meng F; Wang S; Zhong Z
    Adv Mater; 2024 Oct; 36(40):e2409590. PubMed ID: 39194369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
    Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
    ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
    Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
    Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant.
    Cui G; Sun Y; Qu L; Shen C; Sun Y; Meng F; Zheng Y; Zhong Z
    Adv Healthc Mater; 2024 Jul; 13(17):e2303690. PubMed ID: 38458152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy.
    Chen J; Fang H; Hu Y; Wu J; Zhang S; Feng Y; Lin L; Tian H; Chen X
    Bioact Mater; 2022 Jan; 7():167-180. PubMed ID: 34466725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acidity-responsive polyphenol-coordinated nanovaccines for improving tumor immunotherapy
    Qiu H; Wang S; Huang R; Liu X; Li L; Liu Z; Wang A; Ji S; Liang H; Jiang BP; Shen XC
    Biomater Sci; 2024 Jun; 12(12):3175-3192. PubMed ID: 38742916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
    Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
    Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
    Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K
    Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
    Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
    Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer.
    Huang KW; Hsu FF; Qiu JT; Chern GJ; Lee YA; Chang CC; Huang YT; Sung YC; Chiang CC; Huang RL; Lin CC; Dinh TK; Huang HC; Shih YC; Alson D; Lin CY; Lin YC; Chang PC; Lin SY; Chen Y
    Sci Adv; 2020 Jan; 6(3):eaax5032. PubMed ID: 31998834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.